Discover management strategies for alopecia areata, from anti-inflammatory diets to stress reduction techniques that can help ...

Discover AQST's growth potential with Anaphylm's FDA approval by Q2'25 targeting $1B revenue. Learn DCF valuations offering ...

Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported ...

Medically reviewed by Susan Bard, MD Alopecia areata is a common hair loss condition. It affects people of all ages, races, ...

The Food and Drug Administration (FDA) has granted Fast Track designation to bempikibart for the treatment of alopecia areata (AA).

While similarities exist between types of alopecia, distinct clinical characteristics help patients & physicians ...

Retrograde alopecia is a form of hair loss characterized by the gradual thinning or recession of hair at the nape of the neck ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, ...

Bempikibart (ADX-914) is a human anti-IL-7Rα antibody that blocks the IL-7 and TSLP pathways, which have been implicated in driving T cell-mediated pathological processes in autoimmune diseases.